|
1
|
Quintás-Cardama A and Cortes J: Molecular
biology of bcr-abl1-positive chronic myeloid leukemia. Blood.
113:1619–1630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shimada A: Hematological malignancies and
molecular targeting therapy. Eur J Pharmacol. 862:1726412019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holyoake TL and Vetrie D: The chronic
myeloid leukemia stem cell: Stemming the tide of persistence.
Blood. 129:1595–1606. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang W, Hiscox S, Matsumoto K and
Nakamura T: Hepatocyte growth factor/scatter factor, its molecular,
cellular and clinical implications in cancer. Crit Rev Oncol
Hematol. 29:209–248. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pons E, Uphoff CC and Drexler HG:
Expression of hepatocyte growth factor and its receptor c-met in
human leukemia-lymphoma cell lines. Leuk Res. 22:797–804. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY,
Suh JS, Chae SC, Lee KS and Lee KB: Clinical implications of
angiogenic factors in patients with acute or chronic leukemia:
Hepatocyte growth factor levels have prognostic impact, especially
in patients with acute myeloid leukemia. Leuk Lymphoma. 46:885–891.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cerny-Reiterer S, Ghanim V, Hoermann G,
Aichberger KJ, Herrmann H, Muellauer L, Repa A, Sillaber C, Walls
AF, Mayerhofer M and Valent P: Identification of basophils as a
major source of hepatocyte growth factor in chronic myeloid
leukemia: A novel mechanism of BCR-ABL1-independent disease
progression. Neoplasia. 14:572–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corbin AS, Agarwal A, Loriaux M, Cortes J,
Deininger MW and Druker BJ: Human chronic myeloid leukemia stem
cells are insensitive to imatinib despite inhibition of BCR-ABL
activity. J Clin Invest. 121:396–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Crowley LC, Elzinga BM, O'Sullivan GC and
McKenna SL: Autophagy induction by Bcr-Abl-expressing cells
facilitates their recovery from a targeted or nontargeted
treatment. Am J Hematol. 86:38–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu MY, Wang WZ, Liao FF, Wu QQ, Lin XH,
Chen YH, Cheng L, Jin XB and Zhu JY: Selective and effective
targeting of chronic myeloid leukemia stem cells by topoisomerase
II inhibitor etoposide in combination with imatinib mesylate in
vitro. Cell Biol Int. 41:16–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu R, Yu BX, Chen JF, Lv XY, Yan ZJ, Cheng
Y and Ma Q: Anti-tumor effects of Atractylenolide I on bladder
cancer cells. J Exp Clin Cancer Res. 35:402016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu R, Yao J and Ren Y: A novel circRNA,
circNUP98, a potential biomarker, acted as an oncogene via the
miR-567/PRDX3 axis in renal cell carcinoma. J Cell Mol Med.
24:10177–10188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noh H, Park MS, Kim SH, Oh SJ, Zang DY,
Park HL, Cho DJ, Kim DW and Lee JI: Optimization of radotinib doses
for the treatment of Asian patients with chronic myelogenous
leukemia based on dose-response relationship analyses. Leuk
Lymphoma. 57:1856–1864. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mizui M, Isaka Y, Takabatake Y, Mizuno S,
Nakamura T, Ito T, Imai E and Hori M: Electroporation-mediated HGF
gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int.
65:2041–2053. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki A, Hayashida M, Kawano H, Sugimoto
K, Nakano T and Shiraki K: Hepatocyte growth factor promotes cell
survival from fas-mediated cell death in hepatocellular carcinoma
cells via Akt activation and Fas-death-inducing signaling complex
suppression. Hepatology. 32:796–802. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arakaki N, Kazi JA, Kazihara T, Ohnishi T
and Daikuhara Y: Hepatocyte growth factor/scatter factor activates
the apoptosis signaling pathway by increasing caspase-3 activity in
sarcoma 180 cells. Biochem Biophys Res Commun. 245:211–215. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schenk RL, Strasser A and Dewson G: BCL-2:
Long and winding path from discovery to therapeutic target. Biochem
Biophys Res Commun. 482:459–469. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Konturek PC, Konturek SJ, Sulekova Z,
Meixner H, Bielanski W, Starzynska T, Karczewska E, Marlicz K,
Stachura J and Hahn EG: Expression of hepatocyte growth factor,
transforming growth factor alpha, apoptosis related proteins Bax
and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol
Ther. 15:989–999. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yalniz FF and Wierda WG: Targeting BCL2 in
chronic lymphocytic leukemia and other hematologic malignancies.
Drugs. 79:1287–1304. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neri LM, Cani A, Martelli AM, Simioni C,
Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey
JA and Capitani S: Targeting the PI3K/Akt/mTOR signaling pathway in
B-precursor acute lymphoblastic leukemia and its therapeutic
potential. Leukemia. 28:739–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bertacchini J, Heidari N, Mediani L,
Capitani S, Shahjahani M, Ahmadzadeh A and Saki N: Targeting
PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci.
72:2337–2347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen JR, Jia XH, Wang H, Yi YJ, Wang JY
and Li YJ: Timosaponin A-III reverses multi-drug resistance in
human chronic myelogenous leukemia K562/ADM cells via
downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt
signaling pathway. Int J Oncol. 48:2063–2070. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding X, Xi W, Ji J, Cai Q, Jiang J, Shi M,
Yu Y, Zhu Z and Zhang J: HGF derived from cancerassociated
fibroblasts promotes vascularization in gastric cancer via PI3K/AKT
and ERK1/2 signaling. Oncol Rep. 40:1185–1195. 2018.PubMed/NCBI
|
|
25
|
Kuang W, Deng Q, Deng C, Li W, Shu S and
Zhou M: Hepatocyte growth factor induces breast cancer cell
invasion via the PI3K/Akt and p38 MAPK signaling pathways to
up-regulate the expression of COX2. Am J Transl Res. 9:3816–3826.
2017.PubMed/NCBI
|
